No Data
D. Boral Maintains Buy Rating, $128 Target on Biomea Fusion After Presentations
Express News | Biomea Fusion Says In Preclinical Experiments, Icovamenib Enhanced Beta Cell Function And Responsiveness Of Human Islets To GLP-1-Based Therapies
Express News | Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Biomea Fusion Slides As Insider Purchases Lose Another US$26k
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
Biomea Fusion Is Maintained at Buy by D. Boral Capital
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Trytosaveabit OP : Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia
BMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levels
Pharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetration
Preliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recovery (CRi) and reductions in bone marrow blasts in 5 of 6 of the evaluable FLT3 mutated patients